Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK.

Cancer Chemother Pharmacol. 2011 Mar;67(3):657-66. doi: 10.1007/s00280-010-1326-9. Epub 2010 May 28.

2.

Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).

Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C.

Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.

PMID:
19621225
3.

A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.

Zheng L, Li MP, Gou ZP, Wang Y, Xu N, Cai YM, Luo H.

Br J Clin Pharmacol. 2015 Apr;79(4):650-9. doi: 10.1111/bcp.12528.

4.

Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.

Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.

Pediatr Blood Cancer. 2016 Jul;63(7):1207-13. doi: 10.1002/pbc.25983. Epub 2016 Apr 1.

5.

Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.

Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G.

Antivir Ther. 2004 Aug;9(4):491-7.

PMID:
15456079
6.

Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.

Yamazaki N, Uhara H, Wada H, Matsuda K, Yamamoto K, Shimamoto T, Kiyohara Y.

J Dermatol. 2016 Oct;43(10):1146-1153. doi: 10.1111/1346-8138.13338.

7.

Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.

Minutilli E, Feliciani C.

Tumori. 2012 Mar-Apr;98(2):185-90. doi: 10.1700/1088.11928. Review.

PMID:
22677983
8.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group.

Lancet. 2008 Jul 12;372(9633):117-26. doi: 10.1016/S0140-6736(08)61033-8.

9.

Sylatron: a pegylated interferon for use in melanoma.

Patel JN, Walko CM.

Ann Pharmacother. 2012 Jun;46(6):830-8. doi: 10.1345/aph.1Q791. Epub 2012 May 22. Review.

PMID:
22619474
10.

Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.

Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A.

J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum in: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
19433686
11.

Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.

Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH.

Am J Kidney Dis. 2013 Oct;62(4):789-95. doi: 10.1053/j.ajkd.2013.03.037. Epub 2013 Jun 5.

PMID:
23746377
12.

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, Schadendorf D, Patel PM, de Schaetzen G, Spatz A, Keilholz U.

J Clin Oncol. 2012 Nov 1;30(31):3810-8. doi: 10.1200/JCO.2011.41.3799. Epub 2012 Sep 24.

PMID:
23008300
13.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
14.

Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles.

Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, Fagiuoli S.

J Viral Hepat. 2012 Jan;19 Suppl 1:33-6. doi: 10.1111/j.1365-2893.2011.01519.x. Review.

PMID:
22233411
15.

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.

Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H; Nordic Melanoma Cooperative Group.

Lancet Oncol. 2011 Feb;12(2):144-52. doi: 10.1016/S1470-2045(10)70288-6. Epub 2011 Jan 20.

PMID:
21256809
16.

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.

Lancet. 2014 Aug 2;384(9941):414-26. doi: 10.1016/S0140-6736(14)60538-9. Epub 2014 Jun 4. Erratum in: Lancet. 2016 Apr 30;387(10030):1816.

PMID:
24907224
17.

Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.

Mohr P, Hauschild A, Trefzer U, Enk A, Tilgen W, Loquai C, Gogas H, Haalck T, Koller J, Dummer R, Gutzmer R, Brockmeyer N, Hölzle E, Sunderkötter C, Mauch C, Stein A, Schneider LA, Podda M, Göppner D, Schadendorf D, Weichenthal M.

J Clin Oncol. 2015 Dec 1;33(34):4077-84. doi: 10.1200/JCO.2014.59.6932. Epub 2015 Oct 26.

PMID:
26503196
18.

Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial.

Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa-Violante M, Maldonado-Garza H, Pérez-Gómez R, Cabrera-Valdespino A.

Ann Hepatol. 2003 Jul-Sep;2(3):135-9.

PMID:
15115965
19.

Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study.

Bruno R, Sacchi P, Scagnolari C, Torriani F, Maiocchi L, Patruno S, Bellomi F, Filice G, Antonelli G.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):369-76.

20.

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S.

Clin Pharmacol Ther. 2000 Nov;68(5):556-67.

PMID:
11103758

Supplemental Content

Support Center